title: Piperacillin-sulbactam versus piperacillin-tazobactam: a multicentre, randomised, single-blind, controlled clinical trial.
abstract: The objective of this study was to compare the efficacy and safety of piperacillin-sulbactam (PIP-SBT) and piperacillin-tazobactam (PIP-TAZ) in the treatment of bacterial respiratory and urinary tract infections. A randomised, single-blind, controlled clinical trial was performed. Differences in clinical efficacy, bacteriology and safety between the two groups were subjected to statistical analysis, including intent-to-treat (ITT) analysis. A total of 215 cases were enrolled, with 203 complete cases (99 PIP-SBT, 104 PIP-TAZ). A total of 209 cases (103 PIP-SBT, 106 PIP-TAZ) were included in the ITT analysis and a total of 212 cases (104 PIP-SBT, 108 PIP-TAZ) were included in the safety analysis. Overall efficacy rates of PIP-SBT and PIP-TAZ were 93.2% and 93.4%, respectively. Overall bacterial eradication rates of the two groups were 95% and 97.59%, respectively. Among the PIP-SBT group, eight patients (7.69%) had adverse events, including four probable drug-related events. Among the PIP-TAZ group, nine patients (8.33%) had adverse events, including one definitely drug-related and four probable drug-related events. All differences between the two groups were insignificant. PIP-SBT could be a suitable replacement for PIP-TAZ in the therapy of community-acquired respiratory and urinary tract infections caused by beta-lactamase-producing bacterial isolates.
authors.affiliation: Department of Infectious Diseases, West China Hospital, Sichuan University, Wainan Guoxuexiang 37, Chengdu 610041, China.
authors.forename: Zong
authors.initials: Z
authors.lastname: Zhiyong
authors.forename: Lü
authors.initials: L
authors.lastname: Xiaoju
authors.forename: Liu
authors.initials: L
authors.lastname: Yanbin
authors.forename: Yang
authors.initials: Y
authors.lastname: Yao
authors.forename: Yu
authors.initials: Y
authors.lastname: Rujia
authors.forename: Fu
authors.initials: F
authors.lastname: Xueqin
authors.forename: Huang
authors.initials: H
authors.lastname: Wenxiang
authors.forename: Cai
authors.initials: C
authors.lastname: Sufang
authors.forename: Yu
authors.initials: Y
authors.lastname: Zebo
authors.forename: Zeng
authors.initials: Z
authors.lastname: Xingping
authors.forename: Duan
authors.initials: D
authors.lastname: Minggang
authors.forename: Xia
authors.initials: X
authors.lastname: Peiyuan
authors.forename: Zhu
authors.initials: Z
authors.lastname: Weiming
authors.forename: Ji
authors.initials: J
authors.lastname: Xianghui
authors.forename: Zhao
authors.initials: Z
authors.lastname: Hongwen
authors.forename: Chen
authors.initials: C
authors.lastname: Yongchuan
authors.forename: Yin
authors.initials: Y
authors.lastname: Fei
authors.forename: Ni
authors.initials: N
authors.lastname: Zongzan
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use*; D000077725:Piperacillin, Tazobactam Drug Combination; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D016037:Single-Blind Method; D013407:Sulbactam / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D013407:Sulbactam; D010878:Piperacillin